Get Adobe Flash player

(Reuters) — Novo Nordisk's ultra long-acting insulin Tresiba has been recommended for approval by the European Medicines Agency in an important boost for the Danish drugmaker's key new product.

The European endorsement, announced by the London-based agency and the company on Friday, follows regulatory delays for the diabetes treatment in the United States, where the bulk of future sales are expected to be generated.

Read more: Novo Nordisk Wins EU Agency Backing for New Insulin

(Reuters) - An insulin pill, long desired by doctors and diabetes patients but abandoned as not physically viable, could be available by the end of this decade as a tiny Israeli company races a Danish pharmaceutical giant to be first with what could be a multibillion-dollar product.

Read more: Pharma's David and Goliath in Race to Produce Insulin Pill

Hội Nội Tiết- Đái Tháo Đường Miền Trung Việt Nam

Diabetes- Endocrinology- Metabolism Association of central Vietnam

Tổng biên tập: NGƯT.GS.TS. NGUYỄN HẢI THỦY

Liên hệ ban biên tập: 0903574457, email: nhthuy52@gmail.com hoặc admin@dema-cvn.com

Năm xuất bản: 12/2010